R&D News | pharmaphorum

News

Bristol Myers Squibb has reported disappointing results for its checkpoint inhibitor combination Opdualag in an adjuvant melanoma study.

News

Johnson & Johnson and Sanofi's vaccine for preventing invasive disease caused by E coli looks all but defunct after they abandon a phase 3 trial.

News

Novo Nordisk's GLP-1 receptor agonist semaglutide has been shown to help people struggling with alcohol use disorder.

News

Another AI drug discovery venture has emerged from the Google DeepMind team, Latent Labs, with $50m in funding for its protein design platform.

News

Abcuro has raised $200m in financing that should allow it to complete a pivotal trial of ulviprubart for rare disease inclusion body myositis (IBM).

News

Novartis has agreed to buy Anthos from private equity firm Blackstone for $3.1 billion, taking Factor XI inhibitor abelacimab back in-house.